BPG is committed to discovery and dissemination of knowledge
Articles in Press
12/23/2025 4:02:30 AM | Browse: 16 | Download: 0
| Category |
Medicine, General & Internal |
| Manuscript Type |
Case Report |
| Article Title |
Five-year follow-up sustained remission with rituximab in a patient with focal segmental glomerulosclerosis: A case report
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ana Flávia Moura, Paulo Novis Rocha, Daniela Moura-Landim, Jose A Moura Jr and José A Moura-Neto |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ana Flávia Moura, Department of Medicine, Bahiana School of Medicine and Public Health, Av D. Joao VI, Salvador 40290-000, Bahia, Brazil. anaflaviapsouza@gmail.com |
| Key Words |
Glomerulonephritis; Glomeruloesclerosis; Focal segmental glomerulosclerosis; Proteinuria; Rituximab; Case report |
| Core Tip |
This case report describes a patient with steroid- and calcineurin inhibitor-dependent primary focal segmental glomerulosclerosis (FSGS) who achieved complete and sustained remission for five years following a two-dose regimen of rituximab (RTX). The case highlights the potential of RTX as a steroid- and calcineurin inhibitor-sparing agent in adult FSGS, particularly in patients with significant toxicity or dependence on standard immunosuppressive therapy. The extended follow-up adds valuable insight into the long-term efficacy and safety of RTX in this challenging population. |
| Citation |
Moura AF, Rocha PN, Moura-Landim D, Moura Jr JA, Moura-Neto JA. Five-year follow-up sustained remission with rituximab in a patient with focal segmental glomerulosclerosis: A case report. World J Nephrol 2025; In press |
 |
Received |
|
2025-11-17 04:41 |
 |
Peer-Review Started |
|
2025-11-17 07:25 |
 |
First Decision by Editorial Office Director |
|
2025-11-19 10:15 |
 |
Return for Revision |
|
2025-11-19 10:15 |
 |
Revised |
|
2025-12-01 13:56 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2025-12-23 02:35 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2025-12-23 04:02 |
 |
Articles in Press |
|
2025-12-23 04:02 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
2220-6124 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345